Nurix Therapeutics Inc
NASDAQ:NRIX

Watchlist Manager
Nurix Therapeutics Inc Logo
Nurix Therapeutics Inc
NASDAQ:NRIX
Watchlist
Price: 21.79 USD -0.14% Market Closed
Market Cap: 1.5B USD
Have any thoughts about
Nurix Therapeutics Inc?
Write Note

Nurix Therapeutics Inc
Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Nurix Therapeutics Inc
Revenue Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Revenue CAGR 3Y CAGR 5Y CAGR 10Y
Nurix Therapeutics Inc
NASDAQ:NRIX
Revenue
$77m
CAGR 3-Years
63%
CAGR 5-Years
16%
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Revenue
$55.5B
CAGR 3-Years
0%
CAGR 5-Years
11%
CAGR 10-Years
11%
Gilead Sciences Inc
NASDAQ:GILD
Revenue
$28.3B
CAGR 3-Years
1%
CAGR 5-Years
5%
CAGR 10-Years
3%
Amgen Inc
NASDAQ:AMGN
Revenue
$32.5B
CAGR 3-Years
8%
CAGR 5-Years
7%
CAGR 10-Years
5%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Revenue
$10.6B
CAGR 3-Years
14%
CAGR 5-Years
24%
CAGR 10-Years
30%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Revenue
$13.8B
CAGR 3-Years
1%
CAGR 5-Years
16%
CAGR 10-Years
18%
No Stocks Found

Nurix Therapeutics Inc
Glance View

Market Cap
1.5B USD
Industry
Biotechnology

Nurix Therapeutics, Inc. is a biopharmaceutical company. The company is headquartered in San Francisco, California and currently employs 242 full-time employees. The company went IPO on 2020-07-24. The firm is focused on the discovery, development and commercialization of small molecule therapies designed to modulate cellular protein levels as a treatment approach for cancer and other challenging diseases. The company leverages its DELigase, an integrated discovery platform to identify and advance drug candidates targeting E3 ligases. Its drug candidate includes NX-2127, NX-5948, NX-1607, DeTIL-0255, KINASE-CTM3, COVID-CTMs, LIGASE-INH2 and DeCART. Its lead drug candidate, NX-2127, is an orally available Bruton’s tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies. Its lead drug candidate from its E3 ligase inhibitor portfolio, NX-1607, is an orally available Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. Its KINASE-CTM3, a kinase involved in T cell growth and activation to treat T cell malignancies and autoimmune disease.

NRIX Intrinsic Value
10.51 USD
Overvaluation 52%
Intrinsic Value
Price

See Also

What is Nurix Therapeutics Inc's Revenue?
Revenue
77m USD

Based on the financial report for Nov 30, 2023, Nurix Therapeutics Inc's Revenue amounts to 77m USD.

What is Nurix Therapeutics Inc's Revenue growth rate?
Revenue CAGR 5Y
16%

Over the last year, the Revenue growth was 99%. The average annual Revenue growth rates for Nurix Therapeutics Inc have been 63% over the past three years , 16% over the past five years .

Back to Top